Advanced Melanoma Clinical Trial
Official title:
A Study to Evaluate the Safety and Efficacy of PV-001-DV in Combination With Infusion of PV-001-DC in Patients With Advanced Melanoma
The purpose of this arm of the study is to evaluate the safety of PV-001-DC (autologous monocyte-derived dendritic cells pulsed with tumor lysate) when given in combination with PV-001-DV (Dengue Virus-1 strain #45AZ5) at the dose levels that were identified in the prior 2 arms and to determine if the combination can treat advanced melanoma. Patients will have a prescribed amount of PV-001-DV injected into one of their melanoma tumors. Patients will go to the clinic and have a needle placed in a vein. The PV-001-DC product will be infused into the patient's vein. Approximately every 3 weeks, for a total of 4 treatments, patients will receive additional infusions of PV-001-DC Patients will be at the clinic for at least 1 hour following the end of each PV-001-DC infusion and if they feel fine, they may go home. Approximately 49 days after the first infusion, patients will have a scan to see if their tumors have changed in size. Other scans may be performed during the study at different times. Patients will also have their blood and small samples of tumors tested for changes to the immune system. After 365 days, the trial will be completed for that patient.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05039801 -
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT04894994 -
FLX475 in Combination With Ipilimumab in Advanced Melanoma
|
Phase 2 | |
| Completed |
NCT01621490 -
PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
|
Phase 1 | |
| Recruiting |
NCT05098184 -
Study on TIL for the Treatment of Advanced Melanoma
|
Early Phase 1 | |
| Completed |
NCT02177110 -
A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma
|
||
| Completed |
NCT00197912 -
Dendritic Cell Based Therapy of Malignant Melanoma
|
Phase 1/Phase 2 | |
| Completed |
NCT04165967 -
Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma
|
Phase 1 | |
| Recruiting |
NCT04495257 -
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
|
Phase 1 | |
| Recruiting |
NCT05968690 -
Naltrexone and Propranolol Combined With Immunotherapy
|
Phase 1 | |
| Active, not recruiting |
NCT03200847 -
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05105100 -
Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
|
||
| Completed |
NCT02171286 -
The Oncopanel Pilot (TOP) Study
|
N/A | |
| Terminated |
NCT01453361 -
Phase II FANG™ in Advanced Melanoma
|
Phase 2 | |
| Recruiting |
NCT05120024 -
Multicenter Study of Safety and Efficacy of Prolgolimab in Patients With Advanced Melanoma in Routine Clinical Practice
|
||
| Active, not recruiting |
NCT04514484 -
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
|
Phase 1 | |
| Active, not recruiting |
NCT04951583 -
Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma
|
Phase 2 | |
| Recruiting |
NCT06112808 -
A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin
|
Phase 1 | |
| Recruiting |
NCT01614301 -
Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04640545 -
A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma
|
Phase 1 | |
| Not yet recruiting |
NCT05629546 -
Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
|
Phase 1 |